Navigation Links
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. 

The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.  In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel disease
'/>"/>

SOURCE Synergy Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc.
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The College of New Rochelle announced today ... Mid-Hudson Region to be designated as a START-UP NY ... qualified “high-technology” businesses that align with the College’s academic ... been selected for the START-UP NY program and extremely ... economic development in New York by growing business and ...
(Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2
... Diagnostics (NYSE: DGX ), the world,s leading ... that the U.S. Food and Drug Administration (FDA) has ... its STRATIFY JCV ™ Antibody ELISA testing service. ... FDA market authorized for the qualitative detection of antibodies ...
... have new hope in a novel technology now offered ... Case Medical Center.  A team of cancer specialists, led ... the nation to launch a dedicated program using Hyperthermic ... other cancers. Performed immediately following surgery, HIPEC ...
... Calif., Jan. 20, 2012  Genomic Health, Inc. (Nasdaq: ... first clinical decision making study of the Onco type ... Score® (RS) result has a significant impact on treatment ... to be presented at the 2012 Gastrointestinal (GI) Cancers ...
Cached Biology Technology:Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 2Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 3UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 2UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 3Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 2Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 3Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 4Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 5Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium 6
(Date:8/21/2014)... in past decade, GTA still violates Canada,s ozone ... the Greater Toronto Area (GTA) has significantly reduced ... the city continues to violate the Canada-wide standards ... or aggravate health problems such as asthma, emphysema ... of complex photochemical reactions involving volatile organic compounds ...
(Date:8/21/2014)... growing in near darkness use a previously unknown process ... research team led by a Penn State University scientist ... research aimed at improving plant growth, harvesting energy from ... occurring on Lake Erie and other lakes worldwide. A ... Science Express edition of the journal ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  ... to a partnership with Gabriel Health Institute, one ... growing Certified Nursing Assistant preparatory schools. The ... exclusive member of Binary,s LiveScan service provider,s owner/operator ... improve its service capabilities by widening the ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... 22, 2010 -- What can scientists learn from watching ... reading, and happily making new friends? Quite a lot, ... carefully observed this sort of group in a fatigue ... in The Journal of the Acoustical Society of America. ...
... team of researchers led by Carnegie Mellon University,s Manojkumar ... recycle, a critical piece in understanding signaling receptor function. ... first time describes how a signaling receptor travels back ... and internalized. Signaling receptors live on the cell ...
... Researchers at Cleveland Clinic,s Genomic Medicine Institute have revealed multiple ... for Cowden syndrome patients who are predisposed to breast and ... earlier discovery of cancerous tumors, is published in the Dec. ... Association ( JAMA ). Charis Eng, M.D., ...
Cached Biology News:Measuring fatigue through the voice 2Carnegie Mellon researchers discover mechanism for signaling receptor recycling 2Carnegie Mellon researchers discover mechanism for signaling receptor recycling 3Researchers discover genetic predisposition for breast, kidney cancers 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Antibody Diluent for IHC 125 ml...
Quinolinate phosphoribosyltransferase...
JMJD2B Antibody...
Biology Products: